Michael J. Mitchell

Michael J. Mitchell is an Associate Professor in the Department of Bioengineering at the University of Pennsylvania. His research focuses on overcoming biological barriers to drug delivery through biomaterials science, nanotechnology, and cellular engineering. Key areas include mRNA lipid nanoparticle development for cancer therapy, immunotherapy, genome editing, and regenerative medicine. His lab has pioneered placental-targeted drug delivery for in utero treatments and developed scalable microfluidic manufacturing processes for vaccines.

Education:

• PhD in Bioengineering (University of Pennsylvania)
• Postdoctoral Training in Nanomedicine

Research Interests:

Dr. Mitchell’s work integrates biomaterials with biological systems to improve drug delivery efficiency. Current projects include:

• Design of lipid nanoparticles for mRNA and CRISPR delivery
• Targeted therapies for cancer metastasis and cardiovascular disease
• Placenta-specific drug delivery systems for maternal-fetal health
• Bioengineered immune cell therapies using mRNA

Recent Achievements:

In 2021, his lab published breakthrough work on lipid nanoparticles improving mRNA vaccine stability, featured in Penn Today and MIT Technology Review. Collaborations with CHOP and Penn Medicine have advanced in utero mRNA delivery for congenital diseases.

Awards & Grants:

Recipient of NIH grants for nanomedicine research and industry partnerships for vaccine development. Active in translational projects with startup companies for clinical nanotechnology applications.

Labs & Teams:

Lead of the Mitchell Lab at Penn Engineering, which includes over 20 researchers focusing on nanomedicine, biomaterials, and clinical translation.